Tiffany Wallace Advencing Diversity, Equity and Inclusion in the Cancer Workforce at Oncology Policy Summit
National Comprehensive Cancer Network posted on LinkedIn:
“Join us next month in Washington, D.C. to hear from keynote speaker, Tiffany Wallace, PhD, from the National Cancer Institute (NCI). Virtual attendance is also available!
Source: National Comprehensive Cancer Network/LinkedIn
Tiffany Wallace is a Program Director in the Office of the Director of the NCI’s CRCHD. Before joining NCI, Dr. Wallace was an Oncology Scientist at Human Genome Sciences (HGS), a biopharmaceutical corporation acquired by GlaxoSmithKline in 2011. While at HGS she managed oncology research programs and conducted preclinical development of promising cancer therapeutic drugs and biologics.
Dr. Wallace received her PhD in biomedical sciences from the University of Florida in Gainesville. She completed her postdoctoral training in the Laboratory of Human Carcinogenesis at NCI. Her research included identification of biomarkers of aggressive disease in prostate and breast cancers, with a focus on variations between different racial/ethnic groups.